Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.

摘要: Gefiinib and erlotinib are two similar small molecules of selective reversible epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which have been approved for second-line or third-line indication in previously treated advanced Non-small-cell lung cancer (NSCLC) patients. The results comparing the EGFR-TKI with standard platinum-based doublet chemotherapy as first-line treatment NSCLC patients activated EGFR mutation were still controversial. A meta-analysis was performed to derive a more precise estimation these regimens. Finally, six eligible trials involved 1,021 identified. receiving front-line therapy had significantly longer progression-free survival (PFS) than [median PFS 9.5 versus 5.9 months; hazard ratio (HR)=0.37; 95% confidence intervals (CI)=0.27-0.52; p<0.001]. overall response rate (ORR) 66.60%, whereas ORR regimen 30.62%, also statistically significant favor [relative risk (RR)=5.68; CI=3.17-10.18; (OS) numerically received by chemotherapy, although difference did not reach statistical significance (median OS 30.5 vs. 23.6 HR=0.94; CI=0.77-1.15; p=0.57). Comparing achieved PFS, higher harboring mutations, thus, it should be first choice untreated mutation.